Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242806227> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4242806227 endingPage "7014" @default.
- W4242806227 startingPage "7014" @default.
- W4242806227 abstract "7014 Background: BAC, a non-small cell lung cancer (NSCLC) subtype with distinctive clinical, pathologic, and radiographic characteristics, is increasing in incidence, especially among younger non-smoking women. Based on analysis of EGFR pathway expression patterns in BAC specimens from the SWOG Lung repository (Franklin, ASCO 2003) and anecdotal reports of prolonged complete response (CR) of advanced stage BAC to gefitinib, SWOG initiated S0126 to determine potential clinical, radiographic, pathologic, and molecular markers predictive of outcome under the influence of gefitinib therapy. Methods: 138 eligible patients (102 chemo-naive, 36 previously treated) were enrolled. Gefitinib 500 mg PO QD was given until evidence of progression or prohibitive toxicity. Results: Median age: 68.0 (range 34.3–88.6); 51% female; PS 0/1: 86%. Among 67 chemo-naive patients with measurable disease, the response rate (RR) by RECIST is 21%, with 6% CR. In 21 previously treated patients with measurable disease, RR is 10% (0% CR). Data on response by computer assisted image analysis will be presented. Median survival is 12 and 10 months for chemo-naïve and previously treated patients, respectively (p=NS). One year survival is ∼50% in each subgroup. Toxicity: acneiform rash and diarrhea as previously described; potential grade 5 toxicity in three cases of patients with increasing pulmonary consolidation, possible interstitial lung disease secondary to treatment versus disease progression and/or infection. Subset analyses show prolonged survival in females (16 vs 7 months, p=.003) and patients with rash (12 vs 5 months, p=.01). For molecular correlative studies, see Franklin: ASCO 04. Conclusions: 1) Gefitinib demonstrates single-agent activity in advanced BAC in both chemo-naïve and previously treated patients; 2) S0126 represents a large clinical and pathologic database of BAC, and as such is a resource for improving understanding of this unique NSCLC subset; 3) Further studies of EGFR inhibitors in BAC are warranted. (CA32102, CA38926) Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca Southwest Oncology Group" @default.
- W4242806227 created "2022-05-12" @default.
- W4242806227 creator A5010962328 @default.
- W4242806227 creator A5021148471 @default.
- W4242806227 creator A5029123414 @default.
- W4242806227 creator A5036091074 @default.
- W4242806227 creator A5037191612 @default.
- W4242806227 creator A5055082049 @default.
- W4242806227 creator A5074848733 @default.
- W4242806227 creator A5091193947 @default.
- W4242806227 date "2004-07-15" @default.
- W4242806227 modified "2023-09-27" @default.
- W4242806227 title "Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126" @default.
- W4242806227 doi "https://doi.org/10.1200/jco.2004.22.14_suppl.7014" @default.
- W4242806227 hasPublicationYear "2004" @default.
- W4242806227 type Work @default.
- W4242806227 citedByCount "8" @default.
- W4242806227 crossrefType "journal-article" @default.
- W4242806227 hasAuthorship W4242806227A5010962328 @default.
- W4242806227 hasAuthorship W4242806227A5021148471 @default.
- W4242806227 hasAuthorship W4242806227A5029123414 @default.
- W4242806227 hasAuthorship W4242806227A5036091074 @default.
- W4242806227 hasAuthorship W4242806227A5037191612 @default.
- W4242806227 hasAuthorship W4242806227A5055082049 @default.
- W4242806227 hasAuthorship W4242806227A5074848733 @default.
- W4242806227 hasAuthorship W4242806227A5091193947 @default.
- W4242806227 hasConcept C121608353 @default.
- W4242806227 hasConcept C126322002 @default.
- W4242806227 hasConcept C143998085 @default.
- W4242806227 hasConcept C2776256026 @default.
- W4242806227 hasConcept C2778570526 @default.
- W4242806227 hasConcept C2778822529 @default.
- W4242806227 hasConcept C2779134260 @default.
- W4242806227 hasConcept C2779438470 @default.
- W4242806227 hasConcept C2780580887 @default.
- W4242806227 hasConcept C71924100 @default.
- W4242806227 hasConcept C90924648 @default.
- W4242806227 hasConceptScore W4242806227C121608353 @default.
- W4242806227 hasConceptScore W4242806227C126322002 @default.
- W4242806227 hasConceptScore W4242806227C143998085 @default.
- W4242806227 hasConceptScore W4242806227C2776256026 @default.
- W4242806227 hasConceptScore W4242806227C2778570526 @default.
- W4242806227 hasConceptScore W4242806227C2778822529 @default.
- W4242806227 hasConceptScore W4242806227C2779134260 @default.
- W4242806227 hasConceptScore W4242806227C2779438470 @default.
- W4242806227 hasConceptScore W4242806227C2780580887 @default.
- W4242806227 hasConceptScore W4242806227C71924100 @default.
- W4242806227 hasConceptScore W4242806227C90924648 @default.
- W4242806227 hasIssue "14_suppl" @default.
- W4242806227 hasLocation W42428062271 @default.
- W4242806227 hasOpenAccess W4242806227 @default.
- W4242806227 hasPrimaryLocation W42428062271 @default.
- W4242806227 hasRelatedWork W2027737109 @default.
- W4242806227 hasRelatedWork W2069129404 @default.
- W4242806227 hasRelatedWork W2083060521 @default.
- W4242806227 hasRelatedWork W2336397012 @default.
- W4242806227 hasRelatedWork W2358165146 @default.
- W4242806227 hasRelatedWork W2387455091 @default.
- W4242806227 hasRelatedWork W2388106736 @default.
- W4242806227 hasRelatedWork W2460915325 @default.
- W4242806227 hasRelatedWork W2978946191 @default.
- W4242806227 hasRelatedWork W4315780819 @default.
- W4242806227 hasVolume "22" @default.
- W4242806227 isParatext "false" @default.
- W4242806227 isRetracted "false" @default.
- W4242806227 workType "article" @default.